VR Logo

Calliditas Therapeutics AB (CALT) download report


Healthcare | Biotechnology & Pharma Research

Calliditas Therapeutics AB (CALT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.

IPO Date: 05-Jun-2020

Chief Exec. Officer: Ms. Renee Aguiar-Lucander

Chief Financial Officer: Mr. Fredrik Johansson

Listing: NASDAQ: CALT

Country: Sweden

Headquarters: Stockholm,

Website: https://www.calliditas.se

Key Facts

Market cap: $488.36 Mln

Revenue (TTM): kr80.91 Mln

Earnings (TTM): kr-575.22 Mln

Cash: kr825.41 Mln

Total Debt: kr214.49 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $12.55 - 33.19

Shares outstanding: 26,599,100

7 Years Aggregate:

  • CFO: kr-1,142.32 Mln
  • EBITDA: kr-1,289.83 Mln
  • Net Profit: kr-1,293.13 Mln

Stock Performance

Time Period Calliditas Therapeutics AB (CALT) S&P BSE Sensex S&P Small-Cap 600
YTD-26.66-9.18-18.78
1 month0.83-4.78-8.00
3 months-5.12-9.66-13.65
1 Year-38.340.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Calliditas Therapeutics AB (CALT) S&P Small-Cap 600 S&P BSE Sensex
2021-26.3525.2721.99